Objective: This study aims to test the hypothesis that consistently ovulatory premenopausal/perimenopausal women have a more favorable cardiometabolic profile than anovulatory women.
T he final menstrual period (FMP), a woman's entry into menopause, is defined after 1 year of amenorrhea; the period of time leading up to menopauseV perimenopauseVvaries widely between women. Perimenopause typically lasts 4 to 8 years and can be characterized by variable cycle length or occasional skipped cycles in its early stage. Two or more skipped cycles (ie, Q60 d of amenorrhea) define the late stage. 1 As menses become irregular, they also are more likely to be anovulatory. The progression of menstrual cycle types (regular to irregular) as women transition to menopause denotes a shift in ovarian activity to anovulatory cycles and to eventual hypogonadism. 2 Luteal-phase production of progesterone likewise decreases across time. 3 The characteristics of reproductiveage women with respect to menstrual cycle irregularity have been partially documented in the literature. 4, 5 Some evidence has suggested that persistent anovulation, reflective of poor ovarian function, is associated with inferior cardiometabolic health and thus poorer systemic health.
The Women's Ischemia Syndrome Evaluation study 6 demonstrated that women with irregular and infrequent menstrual periods have a greater prevalence of angiographically proven coronary artery disease; however, because Women's Ischemia Syndrome Evaluation study participants were a special preselected population with chest discomfort who were referred for angiographic testing, they differ from the general population. Others have shown that women who undergo early menopause have a worse cardiometabolic profile 7 and are more likely to die at a younger age from heart disease. 8 Taken together, these data imply that consistent estrogen exposure during the final reproductive years is cardioprotective. Whether menstrual irregularity or lower overall estrogen exposure per cycle is associated with adverse cardiometabolic indicators has not been addressed definitively; whether menstrual irregularity has an effect on the cardiometabolic risk factors of previously normally cycling women who become irregular when approaching menopause has neither been addressed, to our knowledge. In a recent cross-sectional study of 951 middle-aged women, diminished ovarian reserve, as measured by antimüllerian hormone levels, was associated with a worse cardiometabolic profile. 9 We hypothesized that consistently ovulatory cycles during the menopausal transition would identify women with a more favorable cardiometabolic profile compared with women who were anovulatory before menopause. To test this hypothesis, we used data from the Study of Women's Health Across the Nation (SWAN) Daily Hormone Study (DHS), which includes a large multiethnic cohort.
METHODS

Study sample
The DHS is an annual substudy of SWAN that began on the second SWAN follow-up year. SWAN is an ongoing multicenter, multiethnic longitudinal study of women as they transition from premenopause to postmenopause. SWAN began in 1994; details about the sampling frame and strategies have been previously published. 10 Screening surveys were administered by telephone based on random digit dialing (Los Angeles, Pittsburgh, and Newark, NJ) or household lists (Boston, Chicago, Detroit, and Oakland). At each site, one third to one half of the women were of a prespecified ethnicity (African American, Chinese, Japanese, or Hispanic); the remaining women were non-Hispanic whites, who were recruited at each site. Eligibility criteria included the following: aged 42 to 52 years, at least one menstrual period and no hormone therapy within the prior 3 months, no current pregnancy or breastfeeding, intact uterus, and at least one ovary. A written informed consent form was obtained from all participants. All appropriate institutional review boards approved the study.
In addition to the core SWAN measurements, which are taken annually, DHS enrollees annually completed a collection of first morning voided urine daily for either an entire menstrual cycle or up to 50 days (whichever comes first). DHS participants did not collect urine samples in the years they were taking exogenous hormone therapy. DHS participants completed the study protocol by either having an FMP or collecting annually through the 10th year. The DHS was stopped then. Currently, data are available through the fourth annual DHS collection.
Laboratory and anthropometric measurements
Chemiluminescent assays were developed to measure urinary luteinizing hormone and follicle-stimulating hormone, as well as metabolites of estradiol (estrone conjugates) and progesterone (pregnanediol glucuronide). 11 All hormones were normalized for creatinine. 12 Cycles were assessed for evidence of luteal activity and for the day of luteal transition using previously developed algorithms 13 ; from this, ovulatory status was determined for each of up to four annual DHS visits.
A woman was categorized as consistently ovulatory annually (COA) if annual collections from DHS year 1 (abbreviated BH1[) through DHS year 4 (abbreviated BH4[) before menopause were observed as ovulatory and if menopause occurred no earlier than the third year of the DHS. A woman was categorized as not consistently ovulatory annually (nCOA) if at least one anovulatory year was observed.
Menopause status was determined annually in SWAN based on reports about frequency of menstrual bleeding, regularity of menstrual bleeding, and use of hormone therapy: (1) premenopauseVmonthly bleeding with no perceived change in cycle interval; (2) early perimenopauseVmonthly bleeding with a perceived change in cycle interval but at least one menstrual period within the past 3 months; (3) late perimenopauseV amenorrhea in the previous 3 months but menses in the previous 11 months; and (4) postmenopauseV12 consecutive months of amenorrhea.
Cardiometabolic profile included measurement of highdensity lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), HDL-CYtoYLDL-C ratio, triglycerides, glucose, Homeostasis Model Assessment, 14 C-reactive protein, and fibrinogen. Lipids, lipoproteins, inflammatory markers, hemostatic markers, and metabolic markers were measured as previously published. 15 Cardiometabolic markers were obtained from the annual SWAN main study visit corresponding to each DHS visit, as indicated by the data coordinating center; DHS visits (from which we determined ovulatory status) were not simultaneous with the annual visit (during which cardiometabolic markers were measured).
Plasminogen activator inhibitor-1 was measured with a sandwich procedure using a solid-phase monoclonal antibody and an enzyme-labeled goat second antiserum for detection (IMUBIND plasma PAI-1 ELISA; American Diagnostica, Greenwich, CT).
Standardized protocols were used to measure blood pressure and waist circumference. Briefly, blood pressure was recorded using a standard mercury sphygmomanometer (with appropriate cuff size determined based on arm circumference) after a 5-minute rest, with the woman in a flat-footed seated position. Two sequential readings were taken on the right arm, with a 2-minute intervening rest; these measures were averaged for each participant. Waist circumference was measured at the umbilicus, with participants wearing nonrestrictive undergarments. Based on National Cholesterol Education Program Adult Treatment Panel III guidelines for women, 16 metabolic syndrome was defined as the presence of three or more of the following criteria: (1) waist circumference of 88 cm or more for white and African-American participants and 80 cm or more for Chinese participants; (2) systolic blood pressure of 130 mm Hg or more, diastolic blood pressure of 85 mm Hg or more, or use of antihypertensive medication; (3) fasting serum glucose level of 100 mg/dL or more (or having ever been diagnosed with diabetes); (4) serum triglycerides level of 150 mg/dL or more or medication for hypertriglyceridemia; and (5) HDL-C of 50 mg/dL or less or use of medication for low HDL-C.
Population for analysis
Of the 3,302 women enrolled in the SWAN longitudinal cohort, 953 consented to be included in the baseline DHS visit. Across the four DHS years used in this analysis, 2,737 cycles had sufficient information for classification according to ovulatory algorithm, corresponding to 81% of the samples. DHS participants were excluded from all analyses if available visits were insufficient to classify a woman as either COA (all annual cycles observed as ovulatory before postmenopause status) or nCOA (at least one nonovulatory cycle observed across H1-H4). More potentially COA women were excluded from the analysis because of a missing year of data; we did not assume that an unobserved year midstudy was ovulatory like the years around it, as research has demonstrated that status varies from year to year. 17 The same pattern of missing data would not have led to the exclusion of a record from the nCOA group. Subanalyses centered at time to menopause included women with FMP date in the database.
Statistical analysis
Women were compared by COA status. Cross-sectional comparisons at baseline used t test for continuous measures and W 2 test for categorical measures. Time to FMP was estimated using the Kaplan-Meier method and compared between the COA group and the nCOA group using log-rank test. Adjusted differences in time to FMP between the COA group and the nCOA group were estimated using a Cox proportional hazards model, adjusted for baseline age and body mass index (BMI).
Cross-sectional comparisons of cardiovascular risks were performed between groups at baseline and on the fourth annual visit (or last available visit before menopause). Cross-sectional adjusted analyses used logistic or linear regression, with results presented as estimated means (95% CI) or as proportions from these models.
For longitudinal comparisons of patterns of continuous cardiometabolic measures (eg, HDL-C, LDL-C, and triglycerides), time was centered at FMP, and a linear mixed-effects regression model was estimated (including longitudinal BMI and age as covariates) and adjusted for within-person variability across 
RESULTS
Based on observations across H1 to H4, 636 women were included in this analysis, with 232 (36%) classified as consistently ovulatory and 404 (64%) classified as not consistently ovulatory. At baseline, the consistently ovulatory women were 2.3 years younger (P G 0.001) and had a BMI that was 1.3 kg/m 2 lower (P = 0.02) than those who were not consistently ovulatory; differences between ethnic groups were not significant ( Table 1 ). Consistently ovulatory women were more likely to have education beyond high school and half as likely to report financial strain. Differences by COA status in rates of current smoking and high Center for Epidemiologic Studies Depression scale score (916) 18 were not significantly different.
Date of FMP was available during all accessible years of SWAN follow-up for 63% of COA women and 69% of nCOA women. Time to FMP was estimated for each group, with time censored at the reported last menstrual period date. If a woman was classified as Bpostmenopausal[ without an FMP date, her time to FMP was censored at the last menstrual period date before being categorized as postmenopausal. Time to menopause was longer for consistently ovulatory women, with a difference in median survival time of 4 years (COA: median, 7.9 y; 95% CI, 7.6-8.1; nCOA: median, 3.9 y; 95% CI, 3.5-4.4 y) ( Fig. 1 ). Time to FMP was estimated in a Cox regression model with covariates (baseline age, BMI, and tobacco use). Consistent ovulation remained a significant predictor, with nCOA women more likely to reach FMP at any moment compared with COA women (hazard ratio, 3.1; 95% CI, 2.5-3.9).
DHS-H1 and DHS-H4 cross-sectional comparisons of cardiometabolic profile differences by COA status were adjusted for current BMI and age. Lower HDL-C levels were observed among consistently ovulatory women both at DHS baseline and at the last available DHS visit before menopause. This difference was significant for a percentage of women with low HDL-C, with higher rates of low HDL-C observed among consistently ovulatory women ( Table 2) . 24 .0 (86) 0.6 Comparisons were adjusted for current body mass index and current age at the indicated visit. DHS, Daily Hormone Study; H1, year 1; H4, year 4; COA, consistently ovulatory annually; nCOA, not consistently ovulatory annually; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; HOMA, Homeostasis Model Assessment; PAI-1, plasminogen activator inhibitor-1; E1c, estrone conjugates; Cr, creatinine; Pdg, pregnanediol glucuronide; FSH, follicle-stimulating hormone; LH, luteinizing hormone; CRP, C-reactive protein; HTN, hypertension; (j) increased; (,) decreased. a The last available cardiovascular visit before menopause for women who reached menopause on or before DHS-H4.
To adjust for potential differences in this cohort caused by proximity to menopause, we estimated the differences in continuous measures of cardiometabolic health in a mixed-effects linear regression model, adjusted for time in years centered at menopause (including only women with known FMP) and current BMI and age at each visit.
Among women with FMP (n = 460) on record, 39% (n = 180) were COA and 61% (n = 280) were nCOA. At the time of FMP, nCOA women were younger by half a year and had a slightly higher BMI. In a mixed-effects longitudinal model adjusted for age and BMI and time centered at the FMP date, nCOA women did not have a metabolic profile that was significantly different from that of COA women in general; Figure 2 indicates (with asterisk and P value) the only two instances where between-group differences were statistically significant.
As the definitions of COA and nCOA could not be extended beyond the first 4 years of the DHS (data are not available at this time), all longitudinal models were repeated on a smaller subset that reached menopause no later than 2 years after H4. This limited sample allows us to more directly compare women at similar stages of perimenopause by their consistency of ovulation in the years before menopause. Among women with FMP who reached menopause no later than 2 years after H4 (n = 247) 12% (n = 30) were consistently ovulatory during DHS-H1 to DHS-H4 and 88% (n = 217) were not. At each time point and for every measure, differences by COA status were not statistically significant (all P 9 0.05). In particular, compared annually during the course of menopause, HDL-C geometric means were closer together and CIs were slightly wider given the smaller sample size; differences were no longer statistically significant (Fig. 3) .
DISCUSSION
Our data do not support the hypothesis that persistent anovulation is associated with inferior cardiometabolic health during the menopausal transition. Contrary to our hypothesis, inconsistently ovulatory women demonstrated higher HDL-C, which is believed to be a sign of superior cardiometabolic health. When the data were examined in alignment with the FMP, the HDL-C trends remained but were no longer significant, although we observed a widening of CIs.
There are several potential explanations for our findings. First, it is possible that ovulatory status does not relate to cardiometabolic profile in perimenopausal women. This would imply that ovarian aging is separate from chronological aging. Chronological aging is clearly associated with reduced insulin sensitivity and worsening lipids and lipoproteins. Based on prior data from reproductive-age women, premature loss of female hormones seems to have consequences on cardiometabolic parameters and seems to be associated with adverse health outcomes. 6<8 It is possible that the duration of menstrual cycle perturbations was too short to allow us to measure any adverse effect of anovulation. It is also possible that anovulatory cycles in the DHS are primarily composed of normoestrogenic cycles and thus any association with lack of estrogen exposure would not be identifiable. However, a substantial proportion of DHS participants experienced their FMP by the H4 collection year, which would be expected to have been preceded by a number of anovulatory hypoestrogenic cycles. Finally, it may be that a single well-characterized menstrual cycle once per year is insufficient evidence for the consistency of ovulatory status. A prior cross-sectional study of the SWAN DHS sample found only minimal associations with cardiovascular risk factors and hormone patterns (ovulatory vs anovulatory), although a positive relationship between HDL-C and both estrone conjugates and pregnanediol glucuronide was observed. 19 Our finding of elevated HDL-C levels in not consistently ovulatory women is consistent with other SWAN data indicating that the late menopausal transition is associated with a transient increase in HDL-C. 20<22 It is unclear whether this transient increase reflects a response to a transient increase in hormones. By all measures, estrogen, on average, decreases at this stage of the transition. 10, 23, 24 However, some womenV particularly those who are overweightVdemonstrate a brief rise in estradiol just before their FMP. 25 However, dehydroepiandrosterone sulfate has demonstrated a notable significant rise in a majority of women in the late menopausal transition, and it is possible that this hormone rise is related to the transient increase in HDL-C. 26 As it has been shown that LDL-C particle size gets smaller in menopause, 27 it is possible that the observed increase in HDL-C does not reflect an increase in largeparticle HDL-C but may reflect an increase in small dense lipoprotein particles, which are known to be relatively more atherogenic.
Another recent work has linked reduced ovarian reserve to cardiometabolic risk during premenopause 9 ; however, these women were younger, and ovarian function was assessed differentlyVby using antimüllerian hormone levels and not menstrual cycle characteristics. It is possible that there are reasons for anovulatory menstrual cycles in proximity to menopause other than decreased ovarian reserve. Strengths of our study include the large number of women in the SWAN DHS and the overall good retention of this subcohort throughout the 4 years of the DHS covered by this study. The multiethnic and community-based nature of the SWAN cohort also makes our data reasonably widely applicable to women in the age range of SWAN. The daily sampling paradigm of the DHS protocol also provides much more information than a single annual serum sampling taken at random points in the cycle and allows us to assess the patterns and dynamics of hormone interactions and features such as ovulation and anovulation.
Our study is limited by the fact that DHS participants were volunteers from the larger cohort and may thus be less broadly representative of SWAN, although few demographic differences were present. 28 The width of CIs in the COA group approaching menopause (Fig. 2 ) and across all time points ( Fig. 3 ) and the trend for greater hypertension among nCOA women highlight that variability and sample size could be driving the nonsignificance of the results.
Because no adjustments were made for multiple comparisons, the originally significant difference observed for HDL-C could be attributed to chance; however, note that 14% (3 of 21) of comparisons (Table 2 ) are significantly different (vs 5%, which would be expected by chance alone). A single cycle studied once a year may not be an adequate reflection of hormone performance throughout the rest of the year. Finally, attrition of the cohort may have led to the introduction of bias, as unhealthier women could have been more likely to drop out, making both groups look healthier and more similar.
CONCLUSIONS
In summary, we have not shown that consistent ovulation across the menopausal transition reflects superior cardiometabolic health. The ovary may age apart from the circulatory system during the menopausal transition. Aligning observations by time to menopause may be a more appropriate way to analyze this population; however, backcalculating time as Btime before menopause[ can only be done retrospectively and is thus less helpful as a tool in characterizing health risk prospectively.
